MTOR and Large vessel vasculitis: Furthermore, the fact that HuMoSCs inhibit the mTOR complex is therapeutically relevant since previous data have shown that the mTORC1 pathway plays a central role in driving T-cell inflammation and vascular injury in large vessel vasculitis (36, 37).